{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:42:10Z","timestamp":1761748930974,"version":"build-2065373602"},"reference-count":24,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate whether the use of a steroid\u2010sparing antiemetic protocol (substituting dexamethasone with olanzapine) affects the incidence of neutropenia and associated hospital admissions in patients receiving bleomycin, etoposide and cisplatin (BEP) chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Records from 108 patients who received BEP at St Bartholomew\u2019s Hospital, London were divided into two groups according to antiemetic regimen. Group 1 (treated 2008\u20132013) were treated with a steroid\u2010containing antiemetic protocol and group 2 (treated 2014\u20132017) were treated according to a steroid\u2010sparing protocol, i.e. using olanzapine. Outcomes included incidence of neutropenia at nadir blood count, severity of neutropenia, hospital admissions attributable to febrile neutropenia (FN) and baseline risk factors associated with FN. Statistical analyses were performed using two\u2010sided chi\u2010squared tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The baseline characteristics of the two groups were balanced with regard to age, gender, histology, and proportion of patients with International Germ Cell Cancer Collaborative Group poor\u2010risk disease. The incidence of neutropenia of any grade (group 1, 96.2%; group 2, 98.1%) was similar, although group 2 had more patients with severe neutropenia than group 2 (77.7% vs 88.8%). There was a significant difference in FN incidence (group 1, 22%; group 2 7.5%;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.030). Most cases of FN occurred in cycle 1. Two baseline characteristics were over\u2010represented in patients who developed FN: female sex and age \u226550\u00a0years.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>By comparing two cohorts who received prophylactic antibiotics, our audit suggests that rates of FN\u2010related admissions were lower in the cohort of patients in whom we employed a steroid\u2010sparing antiemetic protocol.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.15175","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T17:04:35Z","timestamp":1594832675000},"page":"205-211","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Neutropenic sepsis rates in patients receiving bleomycin, etoposide and cisplatin chemotherapy using olanzapine and reduced doses of dexamethasone compared to a standard antiemetic regimen"],"prefix":"10.1111","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4459-6032","authenticated-orcid":false,"given":"Ernese","family":"Gjafa","sequence":"first","affiliation":[{"name":"Department of Medical Oncology St Bartholomew\u2019s Hospital Bart\u2019s Health NHS Trust London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9132-4075","authenticated-orcid":false,"given":"Kenrick","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology University College London Hospital NHS Foundation Trust London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tami","family":"Grunewald","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology University College London Hospital NHS Foundation Trust London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myria","family":"Galazi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology St Bartholomew\u2019s Hospital Bart\u2019s Health NHS Trust London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Skyllberg","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology St Bartholomew\u2019s Hospital Bart\u2019s Health NHS Trust London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Wilson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology St Bartholomew\u2019s Hospital Bart\u2019s Health NHS Trust London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantine","family":"Alifrangis","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology St Bartholomew\u2019s Hospital Bart\u2019s Health NHS Trust London UK"},{"name":"Department of Medical Oncology University College London Hospital NHS Foundation Trust London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Shamash","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology St Bartholomew\u2019s Hospital Bart\u2019s Health NHS Trust London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,8,17]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"https:\/\/www.cancerresearchuk.org\/health\u2010professional\/cancer\u2010statistics\/statistics\u2010by\u2010cancer\u2010type\/testicular\u2010cancer\/incidence#heading\u2010Zero. [Internet]. Available athttps:\/\/www.cancerresearchuk.org\/health\u2010professional\/cancer\u2010statistics\/statistics\u2010by\u2010cancer\u2010type\/testicular\u2010cancer\/incidence#heading\u2010Zero"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt304"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2012.15"},{"issue":"2","key":"e_1_2_7_5_1","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1200\/JCO.1998.16.2.716","article-title":"Filgrastim during combination chemotherapy of patients with poor\u2010prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito\u2010Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom","volume":"16","author":"Fossa SD","year":"1998","journal-title":"J Clin Oncol."},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.6.1629"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21847"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1317"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/943618"},{"key":"e_1_2_7_10_1","unstructured":"London Cancer Network: Antiemetic Guidelines for Adult Patients Receiving Chemotherapy and Radiotherapy.http:\/\/wwwlondoncancerorg\/media\/65597\/antiemetic\u2010guidelines\u2010november\u20102010pdf. Accessed November 2012"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0706547"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.7051"},{"key":"e_1_2_7_13_1","first-page":"e133","article-title":"Febrile neutropenia (FN) rates in metastatic hormone sensitive prostate cancer: the role of antibiotics as primary prophylaxis","author":"Pemberton L","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"e_1_2_7_14_1","first-page":"24","article-title":"Olanzapine: an antiemetic option for chemotherapy\u2010induced nausea and vomiting","volume":"5","author":"Brafford MV","year":"2014","journal-title":"J Adv Pract Oncol."},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw270"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0117"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-28-131"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-84-3-304"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-88-4-564"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.98.21.2307"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0008-8749(84)90247-8"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI107880"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3420-y"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.suponc.2011.05.002"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30678-3"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbju.15175","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.15175","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bju.15175","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.15175","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:10:50Z","timestamp":1761747050000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.15175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,17]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1111\/bju.15175"],"URL":"https:\/\/doi.org\/10.1111\/bju.15175","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"type":"print","value":"1464-4096"},{"type":"electronic","value":"1464-410X"}],"subject":[],"published":{"date-parts":[[2020,8,17]]},"assertion":[{"value":"2020-04-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}